Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin M Ellingson

Showing results (221-230 of 286) with videos related to

Pageof 29
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2024
Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade GliomaKarisa C Schreck, Roy E Strowd, Louis B Nabors, et al.
Neuro-Oncology|September 2, 2016
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trialsBenjamin M Ellingson, Robert J Harris, Davis C Woodworth, et al.
Neuro-Oncology|October 15, 2014
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)Patrick Y Wen, Timothy F Cloughesy, Benjamin M Ellingson, et al.
Neuro-Oncology|January 8, 2023
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survivalBenjamin M Ellingson, Patrick Y Wen, Susan M Chang, et al.
Journal of Neuro-Oncology|April 14, 2025
Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF responseFrancesco Sanvito, Irina Kryukov, Jingwen Yao, et al.
Neurosurgery|March 19, 2024
Noninvasive Autopsy-Validated Tumor Probability Maps Identify Glioma Invasion Beyond Contrast EnhancementSamuel A Bobholz, Allison K Lowman, Jennifer M Connelly, et al.
Neuro-Oncology|December 5, 2021
Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitorsAkifumi Hagiwara, Talia C Oughourlian, Nicholas S Cho, et al.
Neuro-Oncology|November 1, 2020
Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trialsBenjamin M Ellingson, Matthew S Brown, Jerrold L Boxerman, et al.
Neuro-Oncology Advances|August 11, 2021
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastomaBenjamin M Ellingson, Kunal Patel, Chencai Wang, et al.
CNS Oncology|November 13, 2024
Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastomaSonoko Oshima, Jingwen Yao, Samuel Bobholz, et al.
Pageof 29

Showing results (221-230 of 286) with videos related to

Sort By:
Pageof 29
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2024
Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade GliomaKarisa C Schreck, Roy E Strowd, Louis B Nabors, et al.
Neuro-Oncology|September 2, 2016
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trialsBenjamin M Ellingson, Robert J Harris, Davis C Woodworth, et al.
Neuro-Oncology|October 15, 2014
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)Patrick Y Wen, Timothy F Cloughesy, Benjamin M Ellingson, et al.
Neuro-Oncology|January 8, 2023
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survivalBenjamin M Ellingson, Patrick Y Wen, Susan M Chang, et al.
Journal of Neuro-Oncology|April 14, 2025
Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF responseFrancesco Sanvito, Irina Kryukov, Jingwen Yao, et al.
Neurosurgery|March 19, 2024
Noninvasive Autopsy-Validated Tumor Probability Maps Identify Glioma Invasion Beyond Contrast EnhancementSamuel A Bobholz, Allison K Lowman, Jennifer M Connelly, et al.
Neuro-Oncology|December 5, 2021
Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitorsAkifumi Hagiwara, Talia C Oughourlian, Nicholas S Cho, et al.
Neuro-Oncology|November 1, 2020
Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trialsBenjamin M Ellingson, Matthew S Brown, Jerrold L Boxerman, et al.
Neuro-Oncology Advances|August 11, 2021
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastomaBenjamin M Ellingson, Kunal Patel, Chencai Wang, et al.
CNS Oncology|November 13, 2024
Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastomaSonoko Oshima, Jingwen Yao, Samuel Bobholz, et al.
Pageof 29